Fast-growing Juno inks lease on a new HQ

About two years from now, Juno Therapeutics ($JUNO) plans to be settling in at its new headquarters at 400 Dexter Avenue North in Seattle. Alexandria Real Estate, which specializes in building biotech space, is constructing a new building at the site and has reserved 80,000 square feet of office/lab space for Juno, which also gets an option on adding additional space as needed. Juno--one of the hottest biotechs in the industry with a special focus on CAR-T--is getting $145 a foot for tenant improvements with the lease starting out at $3.8 million a year. Statement

Suggested Articles

A new, late-phase analysis of the cholesterol-lowering inclisiran showed that it was able to cut LDL levels by 51% after nearly a year-and-a-half.

The data was highly anticipated, especially since the two partners continued testing after the compound missed its endpoints in phase 2 studies.

Removing the IRE1-alpha gene from beta cells in mouse models of Type 1 diabetes restored normal insulin production, scientists found.